[Clinical study on tongxinluo capsule in treatment of patients with angina pectoris caused by coronary heart disease].
To observe the effects of Tongxinluo capsule (TXLC) in treating angina pectoris (AP) caused by coronary heart disease (CHD) and evaluate its safety. Randomized single-blind controlled design were adopted. Three hundred and forty two patients were treated with TXLC (4 capsules, three times daily), and 150 patients in the control group done with Shuxin oral liquor (SXOL, 20 ml, two times daily). After 4 weeks of treatment, the data of AP, ECG, main symptoms, total effects were collected and evaluated. TXLC appeared to be more effective than SXOL for patients with mild, moderate, severe AP (P < 0.01), except with mild stomach discomfort for a few patients, TXLC has no side effect and toxicity. TXLC is an effective drug in treating AP and has no side effects and toxicity.